Insider Buying: Nautilus Biotechnology, Inc. (NASDAQ:NAUT) CEO Acquires $34,204.96 in Stock

Nautilus Biotechnology, Inc. (NASDAQ:NAUTGet Free Report) CEO Sujal M. Patel bought 12,044 shares of Nautilus Biotechnology stock in a transaction dated Monday, March 11th. The stock was acquired at an average price of $2.84 per share, with a total value of $34,204.96. Following the purchase, the chief executive officer now directly owns 10,064,488 shares of the company’s stock, valued at $28,583,145.92. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website.

Nautilus Biotechnology Stock Down 19.1 %

NAUT traded down $0.57 on Monday, hitting $2.41. The company’s stock had a trading volume of 316,040 shares, compared to its average volume of 82,234. Nautilus Biotechnology, Inc. has a 12 month low of $2.00 and a 12 month high of $4.65. The firm has a market cap of $301.49 million, a P/E ratio of -4.63 and a beta of 1.17. The company’s 50 day simple moving average is $2.89 and its 200-day simple moving average is $2.96.

Nautilus Biotechnology (NASDAQ:NAUTGet Free Report) last posted its quarterly earnings results on Wednesday, February 28th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.02. During the same period in the prior year, the business earned ($0.11) earnings per share. Equities analysts predict that Nautilus Biotechnology, Inc. will post -0.72 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in NAUT. Perceptive Advisors LLC lifted its holdings in shares of Nautilus Biotechnology by 38.2% in the fourth quarter. Perceptive Advisors LLC now owns 12,594,211 shares of the company’s stock worth $37,657,000 after buying an additional 3,483,060 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Nautilus Biotechnology by 83.0% in the 1st quarter. Vanguard Group Inc. now owns 2,351,935 shares of the company’s stock valued at $10,207,000 after purchasing an additional 1,066,638 shares during the period. State Street Corp grew its position in shares of Nautilus Biotechnology by 212.0% during the 2nd quarter. State Street Corp now owns 580,183 shares of the company’s stock valued at $1,561,000 after purchasing an additional 394,228 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Nautilus Biotechnology by 220.4% in the second quarter. Northern Trust Corp now owns 449,598 shares of the company’s stock worth $1,209,000 after purchasing an additional 309,274 shares during the period. Finally, BlackRock Inc. increased its holdings in shares of Nautilus Biotechnology by 9.2% in the second quarter. BlackRock Inc. now owns 3,604,324 shares of the company’s stock worth $13,949,000 after purchasing an additional 302,928 shares during the period. Institutional investors own 35.90% of the company’s stock.

About Nautilus Biotechnology

(Get Free Report)

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.

Read More

Receive News & Ratings for Nautilus Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nautilus Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.